Drug Trial Radar · NCT05938036
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
Last checked: Nov 19, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Dec 1, 2023
Primary completion
May 1, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Aqualung Therapeutics Corp.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
Conditions
- Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAbDrug
Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
ALT-100 (Placebo)Drug
Normal saline solution via IV solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the Safety and tolerability of a single intravenously (IV) infused dose of ALT-100 in participants with moderate to severe ARDS: Incidence and severity of treatment-emergent adverse events (TEAEs) from Day 1 to end of study (EOS).Time frame: Up to 60 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Banner University of Arizona
Tucson, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.